“Antibiotics resistance is an increasing problem, especially on a global scale. And when you have this relatively simple infection which suddenly cannot be treated with antibiotics, the situation can turn serious, sometimes life-threatening,” says researcher behind new study.
ANTIBIOTICS RESISTANCE A new substance has proven useful for treating staphylococcus infections in people with skin lymphoma. This is good news for the patients, but also for the global threat of antibiotics resistance.
Staphylococcus aureus. You may have had it in connection with a wound infection. In most cases, it will pass without treatment, while severe cases may require antibiotics, which kills the bacteria. This is the case for the majority of the population. In fact, many of us – though we feel perfectly fine – carry staphylococci in the nose, a good, moist environment in which the bacteria thrive.
However, more and more staphylococci are becoming resistant to antibiotics (also known as multi resistant staphylococcus aureus or MRSA), and these infections can be difficult to treat.
What is antibiotics resistance?
When antibiotics such as penicillin are incapable of preventing bacteria from spreading, the bacteria are what we call antibiotics resistant. This means that they can spread despite attempts to treat them with antibiotics. Too many antibiotics can make more bacteria resistant, and it is therefore important that antibiotics are used only to treat the most serious infections.
“Antibiotics resistance is an increasing problem, especially on a global scale. And when you have this relatively simple infection which suddenly cannot be treated with antibiotics, the situation can turn serious, sometimes life-threatening,” says Professor Niels Ødum from the LEO Foundation Skin Immunology Research Center at the University of Copenhagen.
Therefore, all over the world, a lot of resources are being invested in fighting antibiotics resistance in staphylococcus aureus infections, and a new study among skin lymphoma patients has produced positive results. A new substance called endolysins has proven capable of killing both resistant and non-resistant staphylococcus aureus – without the need for antibiotics. But we will get back to that.
The discovery is good news to patients with a weak immune system to whom a staphylococcus aureus infection can be serious and, at worst, fatal. But it also adds to the knowledge we have of other forms of treatment.
“To people who are severely ill with e.g. skin lymphoma, staphylococci can be a huge, sometimes insoluble problem, as many are infected with a type of staphylococcus aureus that is resistant to antibiotics,” says Niels Ødum and adds:
“That is why we are careful not to give antibiotics to everyone, because we do not want to have to deal with more resistant bacteria. Therefore, it is important that we find new ways of treating – and not the least to prevent – these infections.”
New substance may be the answer
In some patients, a staphylococcus aureus will cause the cancer to worsen. And even though antibiotics appear to work in some cases, it is not without its problems.
“We can tell that giving high doses of antibiotics to patients with serious infections causes their health, skin and cancer symptoms to improve. But once we stop giving them antibiotics, the symptoms and staphylococci quickly return. Patients experience many adverse effects, and some risk getting resistant bacteria,” says Niels Ødum.
Therefore, treating staphylococcus aureus can be tricky. At worst, cancer patients may die of an infection which doctors are unable to treat.
We are careful not to give antibiotics to everyone, because we do not want to have to deal with more resistant bacteria
Professor Niels Ødum
And this is where endolysins enter the scene, as this new substance may be part of the solution to antibiotics resistance like MRSA.
“This particular endolysin is a brand new, artificially produced enzyme that has been improved several times and designed as a new drug,” explains Postdoc Emil Pallesen, who is first author of the study. He adds:
“The great thing about this enzyme is that it has been designed to penetrate the wall of staphylococcus aureus. This enables it to target and kill the harmful staphylococcus and leave harmless skin bacteria unharmed.”
And that is what made the researchers decide to test the new substance; they expected it to be able to kill both resistant and non-resistant staphylococcus bacteria.
“We have been testing the substance on skin samples from patients, and it does appear to kill staphylococcus aureus from patients. Endolysins do not care whether the bacterium is resistant to antibiotics or not, because it does not work in the same way as antibiotics,” says Niels Ødum and adds:
“The really good news is that our lab tests have showed that endolysins do not just eradicate staphylococcus aureus; they also inhibit their ability to promote cancer growth.”
The Latest Updates from Bing News
Go deeper with Bing News on:
- PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration
Vetophage is a Lyon-based biotechnology company founded in 2017. It develops new tools to detect pathogenic bacteria and alternative solutions to antibiotics based on phages and endolysins to tackle ...
- Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration
PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specialized in veterinar ...
- Researchers pioneer safe nanocarrier system for treating bacterial infections
Endolysins: A potential solution for treating the global problem of resistant S. aureus Mar 17, 2023 Anti-cancer drug derived from fungus shows promise in clinical trials ...
- Introducing Yesterday's Phage Therapy in Today's Medicine
Phage-encoded proteins such as cell wall-degrading endolysins  will be marketed a few years from now in the food industry, the veterinary field and possibly in medicine. They will select ...
- PHAXIAM Provides Business and Financial Update For the First Half of 2023
coli and P. aeruginosa to increase patient resistant infections coverage, and the demonstration a Pre-clinical POC for Endolysins. On September 19, 2023, the company announced the extension of its ...
Go deeper with Bing News on:
- IV Antibiotic Ceftobiprole Under Review for Serious Bacterial Infections
Basilea is seeking approval for 3 indications: Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections (ABSSSI) and ...
- Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
Seeking approval for Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired ...
- Why Would a Boil Grow on Your Inner Thigh-And What Can You Do About It?
Boils are an infection of the hair follicle usually caused by a bacteria known as Staphylococcus aureus (staph). Treating boils that develop on the inner thigh usually involves warm compresses, ...
- New antibiotic ceftobiprole shows promise against resistant staph infections
New research shows that an antibiotic effective for bacterial pneumonia also appears to fight treatment-resistant staph infections.
- Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia
In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated S. aureus bacteremia were randomly assigned in a 1:1 ratio to receive ceftobiprole at a dose of 500 mg ...